Reports indicate that Neurocrine Biosciences is about to acquire Soleno Therapeutics at a price of approximately $2.5 billions, prompting Soleno Therapeutics' shares to surge 30% in pre-market trading.

The market responded enthusiastically to this potential deal, reflecting investors' positive expectations for the strategic integration prospects of the two companies. If this acquisition is successfully completed, it will become a significant merger and acquisition case in the neuroscience field in recent years. By integrating Soleno Therapeutics' R&D pipeline, Neurocrine Biosciences is expected to strengthen its position in the central nervous system therapeutics sector. The significant increase in pre-market trading volume also demonstrates the capital market's high level of attention to industry resource integration.